Rovadicitinib in Chronic GVHD
Updated Results From a Phase Ib/IIa Trial of Rovadicitinib for Glucocorticoid-Refractory or Dependent Chronic Graft-vs-Host Disease

Released: December 16, 2024

Expiration: December 15, 2025

Activity

Progress
1
Course Completed